AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33620378 — intervention group
Group type: EXPERIMENTAL
Intervention: PMI
Number of subjects: 2265
Study 33620434 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CABG
Number of subjects: 4015
Study 33620451 — intervention group
Group type: EXPERIMENTAL
Intervention: Management conservatively (89% of older patients)
Number of subjects: 318
Study 33620451 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with SCAD
Number of subjects: 318
Study 33620559 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-PET/MRI
Number of subjects: 42
Study 33620690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 50
Study 33620690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty Acid Profile
Number of subjects: 50
Study 33620690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ω6:Ω3 Ratio
Number of subjects: 50
Study 33620690 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and EPA Levels
Number of subjects: 50
Study 33620690 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc Oxide Concentration
Number of subjects: 50
Study 33620690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupric Oxide Deficiency
Number of subjects: 50
Study 33620705 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of EDCs in follicular fluid
Number of subjects: 210
Study 33620705 — intervention group
Group type: EXPERIMENTAL
Intervention: EDC exposure
Number of subjects: 210
Study 33620705 — intervention group
Group type: EXPERIMENTAL
Intervention: EDC concentration
Number of subjects: 210
Study 33620705 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' lifestyle factors
Number of subjects: 210
Study 33620705 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential area, source of food products, nicotine or caffeine consumption
Number of subjects: 210
Study 33620904 — intervention group
Group type: EXPERIMENTAL
Intervention: Single purified exosome product (PEP) injection (acute-single)
Number of subjects: 6
Study 33620904 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly PEP injections (acute-weekly, 4 total injections)
Number of subjects: 6
Study 33620904 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed single injection (subacute-single)
Number of subjects: 6
Study 33620906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror during pelvic examination
Number of subjects: 145
Study 33620906 — intervention group
Group type: COMPARATOR
Intervention: No mirror during pelvic examination
Number of subjects: 145
Study 33620918 — intervention group
Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (primary augmentation)
Number of subjects: 1008
Study 33620918 — intervention group
Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (revision augmentation)
Number of subjects: 1008
Study 33620918 — intervention group
Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (primary reconstruction)
Number of subjects: 1008
Study 33620918 — intervention group
Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (revision reconstruction)
Number of subjects: 1008
Study 33621442 — intervention group
Group type: EXPERIMENTAL
Intervention: HHe-3 MRI
Number of subjects: 60
Study 33621600 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin-containing multidrug regimens (including IV amikacin, imipenem or cefoxitin, oral azithromycin, and oral clofazimine if applicable)
Number of subjects: 82
Study 33621600 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amikacin-containing multidrug regimens
Number of subjects: 82
Study 33621837 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management training for VAD patients
Number of subjects: 20
Study 33621908 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI False Belief task
Number of subjects: 53
Study 33621908 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinting Task
Number of subjects: 53
Study 33621914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group psychotherapy (CBGP), n = 25
Number of subjects: 47
Study 33621914 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group (DTCG), n = 22
Number of subjects: 47
Study 33621914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group psychotherapy (CBGP)
Number of subjects: 47
Study 33622344 — intervention group
Group type: EXPERIMENTAL
Intervention: MERLIN robotic system for upper limb rehabilitation
Number of subjects: 9
Study 33622371 — intervention group
Group type: EXPERIMENTAL
Intervention: High TIL treatments (metabolic suppression, hypothermia (< 35 °C), intensive hyperventilation)
Number of subjects: 758
Study 33622371 — intervention group
Group type: EXPERIMENTAL
Intervention: High TIL treatments
Number of subjects: 758
Study 33622371 — intervention group
Group type: EXPERIMENTAL
Intervention: High TIL treatments after day 1
Number of subjects: 758
Study 33622371 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic suppression at any day
Number of subjects: 758
Study 33622393 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain measured at 0 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 3 months after surgery
Number of subjects: 307
Study 33622393 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary surgery
Number of subjects: 307
Study 33622393 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative use of pain medications
Number of subjects: 307
Study 33622393 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dynamic NRS values at 6 h postoperatively
Number of subjects: 307
Study 33622508 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment program (3 to 5 in-person sessions + weekly phone calls supported by a mobile app)
Number of subjects: 33
Study 33622508 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment program
Number of subjects: 33
Study 33623980 — intervention group
Group type: EXPERIMENTAL
Intervention: EXimpaired group (n=20)
Number of subjects: 53
Study 33623980 — intervention group
Group type: COMPARATOR
Intervention: EXadequate group (n=18)
Number of subjects: 53
Study 33624010 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom survey
Number of subjects: 118
Study 33624010 — intervention group
Group type: EXPERIMENTAL
Intervention: Work productivity and activity index questionnaire
Number of subjects: 118
Study 33624010 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 118
Study 33624026 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fasting (n=389, average 42 years of fasting)
Number of subjects: 1957
Study 33624026 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fasting (n=389)
Number of subjects: 1957
Study 33624026 — intervention group
Group type: COMPARATOR
Intervention: Non-fasters (n=1568)
Number of subjects: 1957
Study 33624028 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated neutrophil count >7.8 × 10^9/L
Number of subjects: 2034
Study 33624028 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NL-ratio) >5
Number of subjects: 2034
Study 33624028 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-count/creatinine ratio
Number of subjects: 2034
Study 33624028 — intervention group
Group type: EXPERIMENTAL
Intervention: NL-ratio/creatinine ratio
Number of subjects: 2034
Study 33624028 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 2034
Study 33624028 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher GRACE score 1.0/NL-ratio
Number of subjects: 2034
Study 33624040 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33624069 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CV risk assessment using SCORE
Number of subjects: 1324
Study 33624069 — intervention group
Group type: COMPARATOR
Intervention: Individual risk factors
Number of subjects: 1324
Study 33624130 — intervention group
Group type: EXPERIMENTAL
Intervention: One hour of additional sleep per night
Number of subjects: 406
Study 33624130 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhering to the sleep duration recommendation (9-12 hours)
Number of subjects: 406
Study 33624130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 406
Study 33624223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vanin-1 levels measured by ELISA in trauma patients
Number of subjects: 426
Study 33624223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vanin-1 levels in patients with sepsis
Number of subjects: 426
Study 33624223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma vanin-1 at day 1 after trauma
Number of subjects: 426
Study 33624233 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3022855 (anti-CSF-1R monoclonal antibody) 2.5 mg/kg QW, 0.3 mg/kg QW, 0.6 mg/kg QW, 1.25 mg/kg Q2W, 1.25 mg/kg QW, 100 mg QW, 150 mg QW
Number of subjects: 52
Study 33624513 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood cancer survivors (CCSs)
Number of subjects: 1002
Study 33624513 — intervention group
Group type: COMPARATOR
Intervention: Population-based sample (GHS)
Number of subjects: 1002
Study 33625039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell and gene therapy for HIV disease, specific details on dosage and duration not available.
Number of subjects: 0
Study 33625039 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectored passive immunity, B cell engineering, T cell engineering, specific details on dosage and duration not available.
Number of subjects: 0
Study 33625060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cafedrine hydrochloride (200 mg) and theodrenaline hydrochloride (10 mg) in 2 ml (C/T)
Number of subjects: 0
Study 33625060 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 0
Study 33625125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) for PA-LNPCPs
Number of subjects: 158
Study 33625125 — intervention group
Group type: EXPERIMENTAL
Intervention: Margin thermal ablation at SC1
Number of subjects: 158
Study 33625125 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR) for naive large nonpedunculated colorectal polyps (N-LNPCPs)
Number of subjects: 158
Study 33625125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) for PA-LNPCPs (adjusted for 2-stage EMR)
Number of subjects: 158
Study 33625361 — intervention group
Group type: EXPERIMENTAL
Intervention: AFib 2gether mobile app
Number of subjects: 0
Study 33625366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based strategies delivered in real time
Number of subjects: 0
Study 33625371 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) administered intravenously at a loading dose of 30 mg/kg over 15 minutes, followed by a continuous infusion of 1 mg/kg/hour over the next 12 hours.
Number of subjects: 245
Study 33625371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) administered intravenously in an identical manner to VPA.
Number of subjects: 245
Study 33625371 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 245
Study 33625372 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, automated caregiver mobile phone-delivered text message reminders for vaccination visits.
Number of subjects: 1961
Study 33625372 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (health worker providing child vaccination home-based records and verbal instructions).
Number of subjects: 1961
Study 33625541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral trochlear lengthening osteotomy
Number of subjects: 6
Study 33625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day for 16 weeks
Number of subjects: 32
Study 33625721 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 32
Study 33625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin treatment
Number of subjects: 32
Study 33625743 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous osteosynthesis
Number of subjects: 564
Study 33625743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cable pin system (open or percutaneous surgery)
Number of subjects: 564
Study 33625743 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable implants
Number of subjects: 564
Study 33625743 — intervention group
Group type: COMPARATOR
Intervention: Patellectomy with advancement of vastus medialis obliquus surgery
Number of subjects: 564
Study 33625743 — intervention group
Group type: COMPARATOR
Intervention: New intraoperative reduction technique
Number of subjects: 564
Study 33625743 — intervention group
Group type: COMPARATOR
Intervention: Modified tension band technique
Number of subjects: 564
Study 33625743 — intervention group
Group type: COMPARATOR
Intervention: Adjustable patella claws and absorbable suture
Number of subjects: 564
Study 33625762 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific dual chamber pacemaker with SafeR algorithm activated
Number of subjects: 197
Study 33625762 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-TAVI early high-grade atrioventricular block
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: Oversizing
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: High-grade atrioventricular block during TAVI
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: Early high-grade atrioventricular block (within 6 days)
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding prosthesis
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: Prior right bundle branch block
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: Low implantation
Number of subjects: 197
Study 33625762 — intervention group
Group type: COMPARATOR
Intervention: New or wider left bundle branch block and lengthening of PR interval
Number of subjects: 197
Study 33625799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for nitric oxide and carbon monoxide (DLNO and DLCO) measurements post-COVID-19 infection.
Number of subjects: 0
Study 33625888 — intervention group
Group type: EXPERIMENTAL
Intervention: International camps for education and psychosocial support, details on dosage and duration not available.
Number of subjects: 0
Study 33626238 — intervention group
Group type: COMPARATOR
Intervention: Dacomitinib
Number of subjects: 6
Study 33626238 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 6
Study 33626238 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab + Erlotinib
Number of subjects: 6
Study 33626238 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib + Chemotherapy
Number of subjects: 6
Study 33626238 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 6
Study 33626238 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 6
Study 33626251 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (0.08 mg/kg/day) in low-dose cohort
Number of subjects: 21
Study 33626251 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (0.2 mg/kg/day) in high-dose cohort
Number of subjects: 21
Study 33626251 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 33626253 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel)
Number of subjects: 140
Study 33626360 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-2 test
Number of subjects: 630
Study 33626360 — intervention group
Group type: COMPARATOR
Intervention: C24-2 test
Number of subjects: 630
Study 33626360 — intervention group
Group type: COMPARATOR
Intervention: Pattern standard deviation values from C24-2 test
Number of subjects: 630
Study 33626360 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern standard deviation values from 10-2 test
Number of subjects: 630
Study 33626457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever-range whole body hyperthermia (FRWBH) scheduled weekly during re-irradiation; 5 patients received all cycles of FRWBH.
Number of subjects: 10
Study 33626457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever-range whole body hyperthermia (FRWBH)
Number of subjects: 10
Study 33626457 — intervention group
Group type: COMPARATOR
Intervention: Re-irradiation using volumetric arc hyperfractionated radiotherapy with bi-daily 1.2 Gray (Gy) single fractions and a total dose of 66 Gy to all macroscopic tumor lesions; concomitant chemotherapy mostly with cisplatin (7 patients).
Number of subjects: 10
Study 33626891 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress (assessed using the Perceived Stress Scale - PSS-14)
Number of subjects: 110
Study 33626896 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted mean survival time methods
Number of subjects: 0
Study 33626896 — intervention group
Group type: COMPARATOR
Intervention: Proportional hazards methods
Number of subjects: 0
Study 33627058 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based shared decision-making tool (brochure, website, and recorded patient vignettes) for patients with PAD.
Number of subjects: 0
Study 33627066 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of necrotic core in carotid plaque
Number of subjects: 465
Study 33627066 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD
Number of subjects: 465
Study 33627067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment
Number of subjects: 387
Study 33627067 — intervention group
Group type: EXPERIMENTAL
Intervention: Agitation-sedation assessment
Number of subjects: 387
Study 33627067 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium assessment
Number of subjects: 387
Study 33627067 — intervention group
Group type: COMPARATOR
Intervention: Physician perception of pain assessment
Number of subjects: 387
Study 33627067 — intervention group
Group type: COMPARATOR
Intervention: Physician perception of agitation-sedation assessment
Number of subjects: 387
Study 33627067 — intervention group
Group type: COMPARATOR
Intervention: Physician perception of delirium assessment
Number of subjects: 387
Study 33627095 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Haemophilus influenzae (Hi) at stable timepoints
Number of subjects: 255
Study 33627095 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Moraxella catarrhalis (Mcat) at stable timepoints
Number of subjects: 255
Study 33627095 — intervention group
Group type: COMPARATOR
Intervention: Hi-negative at previous stable timepoints
Number of subjects: 255
Study 33627095 — intervention group
Group type: COMPARATOR
Intervention: Mcat-negative at previous stable timepoints
Number of subjects: 255
Study 33627105 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifibrotic therapy
Number of subjects: 209
Study 33627164 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox (40 µg/kg intravenously on Days 1, 3, and 5 of each 28-day cycle for up to six cycles)
Number of subjects: 80
Study 33627164 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxetumomab pasudotox
Number of subjects: 80
Study 33627169 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP treatment
Number of subjects: 306
Study 33627179 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training intervention (6-month-long, four times a week including endurance, strength, and high-intensity training)
Number of subjects: 0
Study 33627179 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise capacity test and tests of muscular strength
Number of subjects: 0
Study 33627193 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous erector spinae plane block (ESP)
Number of subjects: 24
Study 33627193 — intervention group
Group type: COMPARATOR
Intervention: Intercostal nerve block (ICNB)
Number of subjects: 24
Study 33627192 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin treatment in a randomized controlled trial
Number of subjects: 79
Study 33627192 — intervention group
Group type: COMPARATOR
Intervention: Children with comorbidities
Number of subjects: 79
Study 33627192 — intervention group
Group type: COMPARATOR
Intervention: Children without comorbidities
Number of subjects: 79
Study 33627234 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 21
Study 33627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy in patients with COVID-19
Number of subjects: 106
Study 33627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper GI abnormalities
Number of subjects: 106
Study 33627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower GI endoscopies
Number of subjects: 106
Study 33627313 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimers >1850 ng/mL
Number of subjects: 106
Study 33627313 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of GI symptoms
Number of subjects: 106
Study 33627317 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum calcification propensity measurement using nephelometry
Number of subjects: 0
Study 33627317 — intervention group
Group type: COMPARATOR
Intervention: Retrospective analysis of macrovascular events
Number of subjects: 0
Study 33627355 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-sensitivity cardiac troponin T (hs-cTnT) measurement <5 ng/L
Number of subjects: 1711
Study 33627355 — intervention group
Group type: COMPARATOR
Intervention: Original HEART score
Number of subjects: 1711
Study 33627355 — intervention group
Group type: COMPARATOR
Intervention: Modified HEART score
Number of subjects: 1711
Study 33627355 — intervention group
Group type: COMPARATOR
Intervention: Single rule-out, original HEART group, modified HEART group
Number of subjects: 1711
Study 33627400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-invasive radial balloon aortic valvuloplasty (BAV)
Number of subjects: 330
Study 33627448 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 related practices among dental hygienists
Number of subjects: 0
Study 33627495 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based SVD biomarkers (white matter hypodensities, lacunes, brain atrophy, composite SVD burden score)
Number of subjects: 864
Study 33627495 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised ICH score with SVD markers
Number of subjects: 864
Study 33627495 — intervention group
Group type: COMPARATOR
Intervention: Revised ICH score without SVD markers
Number of subjects: 864
Study 33627609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorption using the CytoSorb adsorber during V-V ECMO.
Number of subjects: 18